OMCL Q1 Earnings Call: Revenue Tops Expectations but Tariff Headwinds Pressure Profit OutlookHealthcare tech company Omnicell (
NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was less impressive, coming in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 27.1% above analysts’ consensus estimates.
3 Russell 2000 Stocks Walking a Fine LineThe Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on.
However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
3 Hated Stocks Skating on Thin IceHitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Omnicell Announces New Products for Perioperative and Clinic Settings
Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell’s connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical and operational outcomes across all settings of care.
Omnicell Opens New Innovation Lab in Austin, Texas
Omnicell, Inc. (Nasdaq:OMCL), (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new technologies that are designed to solve evolving challenges faced by the healthcare industry.
2 Healthcare Stocks with Promising Prospects and 1 to Think Twice AboutPersonal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 13%. This performance was worse than the S&P 500’s 5.5% fall.
Why Omnicell (OMCL) Shares Are Trading Lower TodayShares of healthcare tech company Omnicell (
NASDAQ:OMCL)
fell 17.5% in the afternoon session after the company reported weak first-quarter 2025 results, which featured full-year EPS and EBITDA guidance that fell short of Wall Street's estimates.
Omnicell’s (NASDAQ:OMCL) Q1 Sales Top Estimates But Stock DropsHealthcare tech company Omnicell (
NASDAQ:OMCL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was less impressive, coming in 1.8% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 27.1% above analysts’ consensus estimates.
Omnicell Announces First Quarter 2025 Results
Omnicell, Inc. (
NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025.
Omnicell (OMCL) Q1 Earnings Report Preview: What To Look ForHealthcare tech company Omnicell (
NASDAQ:OMCL)
will be announcing earnings results tomorrow morning. Here’s what to expect.
Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers StocksThe end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Evolent Health (
NYSE:EVH) and the rest of the healthcare technology for providers stocks fared in Q4.
Unpacking Q4 Earnings: Omnicell (NASDAQ:OMCL) In The Context Of Other Healthcare Technology for Providers StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Omnicell (
NASDAQ:OMCL) and the best and worst performers in the healthcare technology for providers industry.
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Keep Off Your RadarThe stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology StocksLet’s dig into the relative performance of Tandem Diabetes (
NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.
Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.
Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To KnowA number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for all countries. This reminded markets that the global trade environment remained volatile, limiting the potential for sustained gains.
Omnicell (OMCL): Buy, Sell, or Hold Post Q4 Earnings?What a brutal six months it’s been for Omnicell. The stock has dropped 24.6% and now trades at $32.45, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer
Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.
Omnicell Announces Chief Financial Officer Transition
Omnicell, Inc. (
NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta will be stepping down from his role as Executive Vice President and Chief Financial Officer, effective September 15, 2025 or until a successor is named. Mr. Etta will continue to serve as Executive Vice President and Chief Financial Officer while Omnicell searches for a new Chief Financial Officer and will work to ensure a smooth transition of his role and responsibilities. The Company has commenced a national search for his successor.
3 Healthcare Stocks Skating on Thin IceHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.3%. This performance is a noticeable divergence from the S&P 500’s 5.1% return.
Astrana Health (ASTH) To Report Earnings Tomorrow: Here Is What To ExpectHealthcare services company Astrana Health
will be reporting results tomorrow afternoon. Here’s what investors should know.
